Vactech
Vactech is a pioneering biotechnology company focused on developing innovative vaccines and diagnostics for immune-mediated diseases such as type 1 diabetes, celiac disease, and enterovirus-related conditions. Since 2001, the company has pursued impactful research rooted in academic excellence and commercial potential, aiming to prevent and treat these diseases through groundbreaking vaccine technologies, including a patented preventive vaccine for type 1 diabetes and virus-like particle (VLP) technology. Vactech collaborates with global academic and industry partners, holds numerous patents, and is committed to transforming healthcare with purpose-driven innovation.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Multivalent inactivated enterovirus vaccine candidate (clinical-stage)
A multivalent, formalin-inactivated vaccine formulation targeting multiple enterovirus serotypes associated with immune-mediated disease; progressed through preclinical efficacy studies and early-phase human clinical trials assessing safety and immunogenicity.
Patented enterovirus diagnostic assays and kit concepts
Diagnostic methods and kit concepts for detecting enterovirus presence and for predicting disease risk or monitoring antiviral therapies; protected by regional and international patents.
Virus-like particle (VLP) technology platform
A VLP-based technology platform used to present antigenic structures for vaccines and as reagents for diagnostics and immunomodulatory applications.
Multivalent inactivated enterovirus vaccine candidate (clinical-stage)
A multivalent, formalin-inactivated vaccine formulation targeting multiple enterovirus serotypes associated with immune-mediated disease; progressed through preclinical efficacy studies and early-phase human clinical trials assessing safety and immunogenicity.
Patented enterovirus diagnostic assays and kit concepts
Diagnostic methods and kit concepts for detecting enterovirus presence and for predicting disease risk or monitoring antiviral therapies; protected by regional and international patents.
Virus-like particle (VLP) technology platform
A VLP-based technology platform used to present antigenic structures for vaccines and as reagents for diagnostics and immunomodulatory applications.
Services
Licensing of enterovirus vaccine platform and coordination of strategic partnerships to advance clinical development and commercialization.
Joint preclinical programs including animal model efficacy testing, immunogenicity assays and histopathology to support translational projects.
Development and licensing of diagnostic assays and kit concepts for early detection of enterovirus infection and risk monitoring for immune-mediated diseases.
Licensing of enterovirus vaccine platform and coordination of strategic partnerships to advance clinical development and commercialization.
Joint preclinical programs including animal model efficacy testing, immunogenicity assays and histopathology to support translational projects.
Development and licensing of diagnostic assays and kit concepts for early detection of enterovirus infection and risk monitoring for immune-mediated diseases.
Expertise Areas
- Vaccine development (enterovirus-focused)
- Preclinical efficacy and safety studies
- Clinical trial management (early-phase)
- Diagnostic assay development
Key Technologies
- Inactivated-virus vaccine production (formalin-inactivated)
- Multivalent vaccine composition design
- Virus-like particles (VLP) platform
- PCR and sequencing for viral RNA detection
News & Updates
Recent research highlights the presence of enteroviruses in pancreatic tissues of individuals with T1D, supporting their role as potential triggers.
Experienced leader with over 25 years in pharmaceutical and medical device industries.
Safety, tolerability, and immunogenicity of PRV-101, a vaccine targeting coxsackie B viruses, published in Diabetologia.
Study shows presence of enteroviruses in pancreatic tissues, supporting their role in T1D development.
Large-scale study supports the link between coxsackie B1 virus and increased risk of T1D.
Vactech received US Patent 7,972,592 B2 for a vaccine preventing T1D by eliminating enterovirus infection risk.
Recent research highlights the presence of enteroviruses in pancreatic tissues of individuals with T1D, supporting their role as potential triggers.
Experienced leader with over 25 years in pharmaceutical and medical device industries.
Safety, tolerability, and immunogenicity of PRV-101, a vaccine targeting coxsackie B viruses, published in Diabetologia.
Study shows presence of enteroviruses in pancreatic tissues, supporting their role in T1D development.
Large-scale study supports the link between coxsackie B1 virus and increased risk of T1D.
Vactech received US Patent 7,972,592 B2 for a vaccine preventing T1D by eliminating enterovirus infection risk.